{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:55:59Z","timestamp":1765230959502},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:00:00Z","timestamp":1334016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00277-012-1457-7","type":"journal-article","created":{"date-parts":[[2012,4,9]],"date-time":"2012-04-09T04:16:31Z","timestamp":1333944991000},"page":"1221-1233","source":"Crossref","is-referenced-by-count":34,"title":["Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes"],"prefix":"10.1007","volume":"91","author":[{"given":"Felicitas","family":"Thol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyang","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Kathrin","family":"Sonntag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Damm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Weissinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Krauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"G\u00f6hring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Schambach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,10]]},"reference":[{"key":"1457_CR1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.hoc.2010.02.005","volume":"24","author":"M Cazzola","year":"2010","unstructured":"Cazzola M, Malcovati L (2010) Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 24:459\u2013468","journal-title":"Hematol Oncol Clin North Am"},{"key":"1457_CR2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079\u20132088","journal-title":"Blood"},{"key":"1457_CR3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","volume":"22","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Shan J, Faderl S et al (2008) A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22:538\u2013543","journal-title":"Leukemia"},{"key":"1457_CR4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol F, Friesen I, Damm F et al (2011) Prognostic Significance of ASXL1 Mutations in patients with myelodysplastic syndromes. J Clin Oncol 29:2499\u20132506","journal-title":"J Clin Oncol"},{"key":"1457_CR5","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496\u20132506","journal-title":"N Engl J Med"},{"key":"1457_CR6","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2006-04-014845","volume":"108","author":"M Heuser","year":"2006","unstructured":"Heuser M, Beutel G, Krauter J et al (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:3898\u20133905","journal-title":"Blood"},{"key":"1457_CR7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2007-03-080523","volume":"110","author":"M Heuser","year":"2007","unstructured":"Heuser M, Argiropoulos B, Kuchenbauer F et al (2007) MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 110:1639\u20131647","journal-title":"Blood"},{"key":"1457_CR8","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2008.20.6110","volume":"27","author":"C Langer","year":"2009","unstructured":"Langer C, Marcucci G, Holland KB et al (2009) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 27:3198\u20133204","journal-title":"J Clin Oncol"},{"key":"1457_CR9","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1182\/blood-2003-02-0359","volume":"102","author":"CD Baldus","year":"2003","unstructured":"Baldus CD, Tanner SM, Ruppert AS et al (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 102:1613\u20131618","journal-title":"Blood"},{"key":"1457_CR10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2005.01.6253","volume":"24","author":"CD Baldus","year":"2006","unstructured":"Baldus CD, Thiede C, Soucek S et al (2006) BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 24:790\u2013797","journal-title":"J Clin Oncol"},{"key":"1457_CR11","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1200\/JCO.2007.10.8720","volume":"25","author":"G Marcucci","year":"2007","unstructured":"Marcucci G, Maharry K, Whitman SP et al (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 25:3337\u20133343","journal-title":"J Clin Oncol"},{"key":"1457_CR12","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","volume":"28","author":"S Groschel","year":"2010","unstructured":"Groschel S, Lugthart S, Schlenk RF et al (2010) High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 28:2101\u20132107","journal-title":"J Clin Oncol"},{"key":"1457_CR13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2010.31.1118","volume":"29","author":"F Damm","year":"2011","unstructured":"Damm F, Oberacker T, Thol F et al (2011) Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol 29:682\u2013689","journal-title":"J Clin Oncol"},{"key":"1457_CR14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2008-11-187724","volume":"114","author":"CM Santamaria","year":"2009","unstructured":"Santamaria CM, Chillon MC, Garcia-Sanz R et al (2009) Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 114:148\u2013152","journal-title":"Blood"},{"key":"1457_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccr.2011.06.020","volume":"20","author":"M Heuser","year":"2011","unstructured":"Heuser M, Yun H, Berg T et al (2011) Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1\/AbdB-like HOX protein complex. Cancer Cell 20:39\u201352","journal-title":"Cancer Cell"},{"issue":"3","key":"1457_CR16","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/leu.2011.228","volume":"26","author":"M Heuser","year":"2012","unstructured":"Heuser M, Berg T, Kuchenbauer F et al (2012) Functional role of BAALC in leukemogenesis. Leukemia 26(3):532\u2013536","journal-title":"Leukemia"},{"key":"1457_CR17","first-page":"1051","volume":"31","author":"CD Baldus","year":"2003","unstructured":"Baldus CD, Tanner SM, Kusewitt DF et al (2003) BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol 31:1051\u20131056","journal-title":"Exp Hematol"},{"key":"1457_CR18","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2010-11-320515","volume":"117","author":"S Tsuzuki","year":"2011","unstructured":"Tsuzuki S, Taguchi O, Seto M (2011) Promotion and maintenance of leukemia by ERG. Blood 117:3858\u20133868","journal-title":"Blood"},{"key":"1457_CR19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1172\/JCI21716","volume":"114","author":"S Buonamici","year":"2004","unstructured":"Buonamici S, Li D, Chi Y et al (2004) EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 114:713\u2013719","journal-title":"J Clin Invest"},{"key":"1457_CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.stem.2008.06.002","volume":"3","author":"S Goyama","year":"2008","unstructured":"Goyama S, Yamamoto G, Shimabe M et al (2008) Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3:207\u2013220","journal-title":"Cell Stem Cell"},{"key":"1457_CR21","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1200\/JCO.2008.20.5328","volume":"27","author":"KH Metzeler","year":"2009","unstructured":"Metzeler KH, Dufour A, Benthaus T et al (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 27:5031\u20135038","journal-title":"J Clin Oncol"},{"key":"1457_CR22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa040465","volume":"350","author":"PJ Valk","year":"2004","unstructured":"Valk PJ, Verhaak RG, Beijen MA et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617\u20131628","journal-title":"N Engl J Med"},{"key":"1457_CR23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002770050488","volume":"78","author":"WK Hofmann","year":"1999","unstructured":"Hofmann WK, Ganser A, Seipelt G et al (1999) Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 78:125\u2013130","journal-title":"Ann Hematol"},{"key":"1457_CR24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","volume":"18","author":"M Stadler","year":"2004","unstructured":"Stadler M, Germing U, Kliche KO et al (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460\u2013465","journal-title":"Leukemia"},{"key":"1457_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","volume":"29","author":"JR Passweg","year":"2011","unstructured":"Passweg JR, Giagounidis AA, Simcock M et al (2011) Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care\u2014SAKK 33\/99. J Clin Oncol 29:303\u2013309","journal-title":"J Clin Oncol"},{"key":"1457_CR26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0609.1989.tb00300.x","volume":"43","author":"J Porter","year":"1989","unstructured":"Porter J (1989) Oral iron chelators: prospects for future development. Eur J Haematol 43:271\u2013285","journal-title":"Eur J Haematol"},{"key":"1457_CR27","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","volume":"115","author":"WC Chou","year":"2010","unstructured":"Chou WC, Huang HH, Hou HA et al (2010) Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 115:2749\u20132754","journal-title":"Blood"},{"key":"1457_CR28","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","volume":"95","author":"F Thol","year":"2010","unstructured":"Thol F, Weissinger EM, Krauter J et al (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95:1668\u20131674","journal-title":"Haematologica"},{"key":"1457_CR29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2010-03-272146","volume":"116","author":"F Thol","year":"2010","unstructured":"Thol F, Damm F, Wagner K et al (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116:614\u2013616","journal-title":"Blood"},{"key":"1457_CR30","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol F, Damm F, L\u00fcdeking A et al (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29:2889\u20132896","journal-title":"J Clin Oncol"},{"key":"1457_CR31","doi-asserted-by":"crossref","unstructured":"Damm F, Thol F, Kosmider O et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2011; Advance Online Publication","DOI":"10.1038\/leu.2011.321"},{"key":"1457_CR32","doi-asserted-by":"crossref","unstructured":"Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL et al (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101:837\u2013845","DOI":"10.1182\/blood-2002-05-1459"},{"key":"1457_CR33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2008-10-187203","volume":"114","author":"KI Mills","year":"2009","unstructured":"Mills KI, Kohlmann A, Williams PM et al (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063\u20131072","journal-title":"Blood"},{"key":"1457_CR34","doi-asserted-by":"crossref","first-page":"D562","DOI":"10.1093\/nar\/gki022","volume":"33","author":"T Barrett","year":"2005","unstructured":"Barrett T, Suzek TO, Troup DB et al (2005) NCBI GEO: mining millions of expression profiles\u2014database and tools. Nucleic Acids Res 33:D562\u2013D566","journal-title":"Nucleic Acids Res"},{"key":"1457_CR35","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545\u201315550","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1457_CR36","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/blood-2006-10-053850","volume":"110","author":"JW Cui","year":"2007","unstructured":"Cui JW, Li YJ, Sarkar A et al (2007) Retroviral insertional activation of the Fli-3 locus in erythroleukemias encoding a cluster of microRNAs that convert Epo-induced differentiation to proliferation. Blood 110:2631\u20132640","journal-title":"Blood"},{"key":"1457_CR37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cyto.a.21072","volume":"79","author":"U Tiemann","year":"2011","unstructured":"Tiemann U, Sgodda M, Warlich E et al (2011) Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells. Cytometry A 79:426\u2013435","journal-title":"Cytometry A"},{"key":"1457_CR38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/sim.4780050306","volume":"5","author":"EL Korn","year":"1986","unstructured":"Korn EL (1986) Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255\u2013260","journal-title":"Stat Med"},{"key":"1457_CR39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D Cox","year":"1972","unstructured":"Cox D (1972) Regression models and life tables. J R Stat Soc B 34:187\u2013202","journal-title":"J R Stat Soc B"},{"key":"1457_CR40","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3324\/haematol.2011.045559","volume":"96","author":"F Thol","year":"2011","unstructured":"Thol F, Winschel C, Ludeking A et al (2011) Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 96:1870\u20131873","journal-title":"Haematologica"},{"key":"1457_CR41","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.stem.2010.07.016","volume":"7","author":"NK Wilson","year":"2010","unstructured":"Wilson NK, Foster SD, Wang X et al (2010) Combinatorial transcriptional control in blood stem\/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 7:532\u2013544","journal-title":"Cell Stem Cell"},{"key":"1457_CR42","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood-2009-02-205443","volume":"114","author":"A Kandilci","year":"2009","unstructured":"Kandilci A, Grosveld GC (2009) Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation. Blood 114:1596\u20131606","journal-title":"Blood"},{"key":"1457_CR43","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1158\/0008-5472.CAN-09-0075","volume":"69","author":"S Salek-Ardakani","year":"2009","unstructured":"Salek-Ardakani S, Smooha G, de Boer J et al (2009) ERG is a megakaryocytic oncogene. Cancer Res 69:4665\u20134673","journal-title":"Cancer Res"},{"key":"1457_CR44","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1182\/blood-2010-12-317990","volume":"117","author":"JA Thoms","year":"2011","unstructured":"Thoms JA, Birger Y, Foster S et al (2011) ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer. Blood 117:7079\u20137089","journal-title":"Blood"},{"key":"1457_CR45","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2008.118","volume":"22","author":"U Modlich","year":"2008","unstructured":"Modlich U, Schambach A, Brugman MH et al (2008) Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 22:1519\u20131528","journal-title":"Leukemia"},{"key":"1457_CR46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","volume":"16","author":"S Stein","year":"2010","unstructured":"Stein S, Ott MG, Schultze-Strasser S et al (2010) Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16:198\u2013204","journal-title":"Nat Med"},{"key":"1457_CR47","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1084\/jem.20110447","volume":"208","author":"K Kataoka","year":"2011","unstructured":"Kataoka K, Sato T, Yoshimi A et al (2011) Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med 208:2403\u20132416","journal-title":"J Exp Med"},{"key":"1457_CR48","first-page":"2501","volume":"118","author":"T Pradee","year":"2011","unstructured":"Pradee T (2011) Over Expression of MN1 accelerates leukemia onset and confers resistance to chemotherapy by suppression of p53 and Bim. ASH Abstract 118:2501","journal-title":"ASH Abstract"},{"key":"1457_CR49","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/leu.2010.31","volume":"24","author":"A Pellagatti","year":"2010","unstructured":"Pellagatti A, Cazzola M, Giagounidis A et al (2010) Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24:756\u2013764","journal-title":"Leukemia"},{"key":"1457_CR50","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2141.2010.08174.x","volume":"149","author":"M Nikpour","year":"2010","unstructured":"Nikpour M, Pellagatti A, Liu A et al (2010) Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. Br J Haematol 149:844\u2013854","journal-title":"Br J Haematol"},{"key":"1457_CR51","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J et al (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365:1384\u20131395","journal-title":"N Engl J Med"},{"key":"1457_CR52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64\u201369","journal-title":"Nature"},{"key":"1457_CR53","doi-asserted-by":"crossref","unstructured":"Thol F, Kade S, Schlarmann C et al (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. doi: 10.1182\/blood-2011-12-399337","DOI":"10.1182\/blood-2011-12-399337"},{"key":"1457_CR54","doi-asserted-by":"crossref","unstructured":"Damm F, Kosmider O, Gelsi-Boyer V et al (2012) Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. doi: 10.1182\/blood-2011-12-400994","DOI":"10.1182\/blood-2011-12-400994"},{"key":"1457_CR55","doi-asserted-by":"crossref","unstructured":"Makishima H, Visconte V, Sakaguchi H et al (2012) Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. doi: 10.1182\/blood-2011-12-399774","DOI":"10.1182\/blood-2011-12-399774"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1457-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-012-1457-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1457-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:44:52Z","timestamp":1713833092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1457-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,10]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1457-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,10]]}}}